Le Lézard
Classified in: Health, Covid-19 virus
Subject: MRR

Global Organ-on-a-Chip Markets Research Report 2022 with Profiles of Leading Players - 4Dcell, BiomimX, Emulate, Kirkstall, Nortis and TissUse


DUBLIN, June 29, 2022 /PRNewswire/ -- The "Organ-on-a-Chip: Global Markets" report has been added to ResearchAndMarkets.com's offering.

Research and Markets Logo

The scope of this report covers various types of products available in the organ-on-a-chip market and potential application sectors in various industries. The organ-on-a-chip market is broken down into various segments.

An organ-on-a-chip is a type of artificial organ that possesses the capability to simulate activities, mechanics and physiological responses similar to that of an organ system. These are multi-channel 3D microfluidic cell culture chips that are primarily being used in life science and drug development research because of their ability to imitate human microenvironments in vitro.

The unique characteristics of organ-on-a-chip are worked out by integrating biology and advanced engineering. Cell biology, microfluidics and microfabrication are the core fields that have paved the way towards the development of organ-on-a-chip technology.

Organ-on-a-chip is considered to be a potential game-changing technology and is serving as a testing alternative that is replacing the use of animals in life science research, toxicology testing and drug development studies around the globe. Countries are focusing on this upcoming technology to produce safer and effective drugs.

It has been observed that pharmaceutical R&D expenses create a lot of burden on the healthcare industry because the drug discovery process requires huge investment but has a low success rate. Studies have indicated that using organ-on-a-chips for drug discovery and development studies will help to reduce the cost by 26% because many ineffective and toxic drugs can be eliminated at the preclinical stage before they enter human trials.

Also, rising demand for personalized medicines is also a contributing factor to growth in the organ-on-a-chip market. There are many diseases that still do not have any approved therapies for cures and depend only on symptomatic management, e.g., amyotrophic lateral sclerosis, cirrhosis, etc.

Therefore, organ-on-a-chip will be beneficial for such indications. More research and the increasing prevalence of cancer as well as neurogenerative diseases such as Alzheimer's, Parkinson's disease and other rare indications will also be contributing factors for the market.

The North American region has the highest share of the organ-on-a-chip market, followed by Europe. This is because of the extensive research and developmental activities taking place in the region as well as the presence of major players, funding and the increasing prevalence of chronic diseases. All these factors contribute to growth in the organ-on-a-chip market.

It has been observed that the COVID-19 pandemic had a positive impact on the organ-on-a-chip market. This is because, due to the pandemic, many institutions across the world began research projects aimed at gaining an understanding of disease pathology and developing treatment options for coronavirus.

Finally, it has also been observed that companies are now moving from single organ on a chip to multiple organ on a chip to gain a better understanding of the toxicological impact of a drug.

Revenue forecasts from 2019 to 2026 are given for each type, application, offering and end user.The application segment is characterized by various types, including drug discovery and development, toxicological research, and physiological model development, and by end-use industry, including academic and research institutes, pharmaceutical and biotechnology companies, cosmetics industry and other end users. By type market is segmented to liver, lung, kidney, heart and others. The report also focuses on regional segmentation of the market.

Further, it explains the major drivers and regional dynamics of the global market and current trends within the industry. It also includes information about the industry structure and competitive landscape as well as the impact of COVID-19 on the market. The report includes detailed profiles of the major players in the global organ-on-a-chip market.

Report Includes

Key Topics Covered:

Chapter 1 Introduction

Chapter 2 Summary and Highlights

Chapter 3 Market and Technology Background

Chapter 4 Market Dynamics

Chapter 5 Impact of Covid-19

Chapter 6 Global Organ-On-A-Chip Market by Type

Chapter 7 Global Organ-On-A-Chip Market by End-user

Chapter 8 Global Organ-On-A-Chip Market by Offering

Chapter 9 Global Organ-On-A-Chip Market by Application

Chapter 10 Global Organ-On-A-Chip Market by Region

Chapter 11 Industry Structure

Chapter 12 Company Profiles

For more information about this report visit https://www.researchandmarkets.com/r/3kaps9

Media Contact:

Research and Markets
Laura Wood, Senior Manager
[email protected]

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

Logo: https://mma.prnewswire.com/media/539438/Research_and_Markets_Logo.jpg

SOURCE Research and Markets


These press releases may also interest you

at 01:20
Biophytis SA (Euronext Growth Paris:ALBPS), ("Biophytis" or the "Company"), a clinical-stage biotechnology company specialized in thedevelopment oftherapeutics for age-related diseases, today annouces that it will change the ratio...

18 avr 2024
The report titled "Clinical Trials Matching Software Market by Functionality (Analytics & Reporting, Compliance Tracking, Data Management), Deployment (Cloud & Web Based, On-Premise), End-Use - Global Forecast 2024-2030" is now available on...

18 avr 2024
South Korea's biotechnology company Hyundai Bioscience (CEO Oh Sang-gi, www.hyundaibioscience.com) announced on April 15 that it would carry out global clinical tests aimed at treating all serotypes of Dengue virus infection....

18 avr 2024
The economic turmoil triggered by the COVID-19 pandemic has led to a sharp decrease in the number of self-employed individuals in the United States, with a 22% reduction...

18 avr 2024
WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of common stock of QuidelOrtho Corporation between February 18, 2022 and April 1, 2024, both dates inclusive (the "Class...

18 avr 2024
Takeda (TSE:4502/NYSE:TAK) today announced that the U.S. Food and Drug Administration (FDA) has approved ENTYVIO® (vedolizumab) subcutaneous (SC) administration for maintenance therapy in adults with moderately to severely active Crohn's disease (CD)...



News published on and distributed by: